Literature DB >> 19878732

The role of budesonide/formoterol for maintenance and relief in the management of asthma.

Alan Kaplan1, Dermot Ryan.   

Abstract

The aim of asthma management is to gain and maintain asthma control and reduce the risk of future exacerbations. However, despite the availability of effective therapies and national and international guidelines for their use, many patients remain inadequately controlled and continue to endure and accept a reduced quality of life. This review discusses current challenges in asthma management facing primary care physicians and provides insight into new treatment strategies developed to improve asthma control. A web-based literature review was undertaken with a focus on studies and reviews discussing asthma control and management with traditional therapies and new therapies, including a novel treatment approach using budesonide/formoterol maintenance and reliever therapy. One of the most common problems in long-term asthma control is poor adherence to inhaled corticosteroid (ICS) maintenance therapy, resulting in under-treatment of inflammation. Many patients tend to over-rely on short-acting beta(2)-agonist medication for quick relief of symptoms at the expense of ICS therapy, thus lowering anti-inflammatory protection and increasing the propensity for the development of severe and potentially life-threatening exacerbations. New simplified treatment strategies have been investigated with the aim of overcoming many of these primary care challenges, ultimately improving asthma control and reducing the future risk of exacerbations. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878732     DOI: 10.1016/j.pupt.2009.10.011

Source DB:  PubMed          Journal:  Pulm Pharmacol Ther        ISSN: 1094-5539            Impact factor:   3.410


  2 in total

1.  Antiasthmatic effects of hesperidin, a potential Th2 cytokine antagonist, in a mouse model of allergic asthma.

Authors:  Seung-Hyung Kim; Bok-Kyu Kim; Young-Cheol Lee
Journal:  Mediators Inflamm       Date:  2011-05-04       Impact factor: 4.711

2.  A randomized open-label trial on the use of budesonide/formoterol (Symbicort®) as an alternative reliever medication for mild to moderate asthmatic attacks.

Authors:  Keng Sheng Chew; Hamizah Kamarudin; Che Wan Hashim
Journal:  Int J Emerg Med       Date:  2012-04-13
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.